“showed a trend”

96.1(± 58.2) mg/dL; p = 0.014), and showed a trend toward more severe fibrosis (LSM 15.6(± 19.5) vs. 12.0(± 15.7) kPa; p = 0.115).

Although patients with CD24(−) tumors showed a trend towards longer overall survival trend, the difference was not significant (Figure 3 B; log-rank test, P = 0.115).

SG-based combination therapy showed a trend to improved PFS compared to monotherapy, both in TNBC (14.2 vs 4.6 months, HR = 0.51, p = 0.115) and HoR+HER2− patients (11.3 vs 5.8 months, HR = 0.35, p = 0.159; Supplemental Figure 2 ).

At 10 weeks HFD mice already showed a trend towards reduced burying activity (21 ± 7; control: 29 ± 7, p = 0.1151), and after 30 weeks of diet, the HFD mice demonstrated significantly reduced activity compared to age-matched controls (10 ± 7; control: 20 ± 9; p = 0.0004).

The interaction between group of participants and effects showed a trend toward significance ( F (2,66) = 2.357, P = 0.116, Greenhouse-Geisser correction) and a plot of this 2-way interaction showed a reduced CE and an incremental AE and OE effect for the touch group (see Figure 2 ); pairwise, post hoc comparisons revealed a trend towards significance when considering C

Rats treated with 10 mg/kg intraperitoneal (IP) injection of the NBMPR prodrug, 6‐nitrobenzylthioinosine 5′‐monophosphate (NBMPR‐P), or vehicle, followed by an intravenous (IV) bolus 10 mg/kg dose of clofarabine, showed a trend toward a lower testis concentration of clofarabine than vehicle (1.81 ± 0.59 vs. 2.65 ± 0.92 ng/mg tissue; p = .1160).

Patients with progression to the first treatment showed a trend towards shorter PFS, which was not statistically significant (4.5 months [95% CI: 2.4–6.6 months] vs. 7 months [95% CI: 1.6–12.4 months], p = 0.116).

LC showed a trend for a correlation to BED2 (p = 0.1167).

Although the Ki-67 index also showed a trend toward association with axillary pCR (OR = 0.96; 95% CI: 0.90–1.01, p = 0.117), it did not reach statistical significance on the univariate analysis.

Table 5 shows that there is no statistically significant difference for age, gender ratio, logistic EuroSCORE risk, EQ-5D and EQ-VAS between the patients with or without 2-year QoL information, with the exception of a statistically significantly higher proportion of sedentary patients without 2-year QoL information (52 versus 30 %, p = 0.021). The 57 patients with complete preoperative and 2-year postoperative QoL information showed a trend to an increase for the EQ-5D from 0.72 ± 0.25 (0.80), 0.07–1.00 preoperative to 0.77 ± 0.24 (0.02–1.00) postoperative ( p = 0.117).

Adjuvant chemotherapy showed a trend toward improved disease-free survival (DFS) in both the primary cohort (P = 0.117, log-rank test) and the validation cohort (P = 0.342), but these did not reach statistical significance individually.

Preoperative therapy regimens of NAC with CRT/SRT showed a trend towards an increased response to preoperative therapy ( P = 0.1178; OR, 2.9; 95% CI, 0.8–12.3, Table 2 ).

Total Neoadjuvant Therapy In a cohort of 85 LARC patients (many of whom were treated with TNT) undergoing serial plasma ctDNA assessments, TNT showed a trend towards an increased tumor response (odds ratio or OR 2.9, 95% CI 0.8–12.3, p = 0.1178), but there was no association between pre-neoadjuvant therapy and post-neoadjuvant therapy ctDNA status and tumor response [ 57 ].

As shown in Fig 4 , relative expression of miR-133b compared to untreated controls showed a trend of upregulation of 2.3-fold when treated with 1μm 5-Aza-2’-C (p = 0.1179).

Analysis of all cases showed a trend toward better prognosis for H3K27M mutation cases (P=0.118), while TERT was significantly worse for the mutation type with 29.2 months for wild type vs. 9.3 months for the mutation type (P=0.026).

The net ABM‐PLBM effect showed a trend of decreasing skin roughness that was not statistically significant at T1 ( P = 0.1180) but was statistically significant at T2, when a decrease of about 9% ( P = 0.0000) was observed, as shown in Figure 5 .

The comparison of some clinical characteristics between the patients with different genotypes showed a trend for longer survival of patients with 6A/6A genotype compared to the carriers of 5A allele ( 5A/5A+5A/6A genotypes, p = 0.118, Log rank test).

Among the other nondriver genes analyzed by NGS, TET2 mutated patients (3/51; 5.9%) showed a trend toward a higher SS compared to TET2 wild-type patients (38.0 kPa vs. 25.2 kPa, respectively; p =0.118).

ESKD females with LVH (33.5 (7.9–70.9) ng/mL) showed significantly lower ( p = 0.045) leptin values than ESKD females without LVH (48.8 (20.8–138.1) ng/mL); males with LVH (6.8 (2.3–15.0) ng/mL) showed a trend towards lower values ( p = 0.118) when compared to males without LVH (8.9 (4.9–25.7) ng/mL).

In large trajectories, NK cells showed a trend migrated faster at 1.94 ± 0.2 μm/min on pTNF-treated PAECs versus 1.5 ± 0.23 μm/min on control PAECs, P = 0.1184 (Fig. 4 F, right).

However, Bugu-M showed a trend to increase the time of the mice into the novel arm relative to 3×Tg-AD group ( p = 0.1185; Fig. 6D ).

We showed a trend towards a greater probability of having a MDR bacteria isolated in ascitic fluid culture of the patients on SBP prophylaxis (55.5 vs. 26.5%; p = 0.119).

Similarly, ASA class showed a trend toward increased odds of severe complications in patients classified as ASA 3 (OR: 4.261, p = 0.119) and ASA 4 (OR: 13.059, p = 0.109), but these results were not statistically significant.

In this cohort IgM-RF positivity was not associated with the development of arthritis, and ACPA-positivity showed a trend towards a predictive association (HR (95% CI): 2.7 (0.8 to 9.7); p=0.119), but did not have predictive value over and above smoking and/or BMI.

However, their data showed a trend towards higher birth rates in NC-FET (37.6 vs 30.1%, P = 0.119).